Treatment of masseteric hypertrophy with botulinum toxin: A report of two cases

Baş, Burcu; Ozan, Bora; Muğlalı, Mehtap; Çelebi, Nükhet

doi:10.4317/medoral.15.e649

Cited by 40 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical diagnosis of hypertrophy is often accompanied by difficulty in appropriate confirmation due to vague standards, so diagnosis may depend entirely upon the evaluations of clinicians. In addition, severe or frequent tooth‐clenching during wakefulness is known as one of the most important contributors to morphological change, such as masseter muscle hypertrophy (Bas et al ., ; Clark et al ., ; Kato and Lavigne, ). In fact, this clinical sign was also found in our control subjects.…”

Section: Discussionmentioning

confidence: 99%

Association between patterns of jaw motor activity during sleep and clinical signs and symptoms of sleep bruxism

Yoshida

Suganuma

Takaba

et al. 2016

Journal of Sleep Research

View full text Add to dashboard Cite

The aim of this study was to investigate the association between patterns of jaw motor activity during sleep and clinical signs and symptoms of sleep bruxism. A total of 35 university students and staff members participated in this study after providing informed consent. All participants were divided into either a sleep bruxism group (n = 21) or a control group (n = 14), based on the following clinical diagnostic criteria: (1) reports of tooth-grinding sounds for at least two nights a week during the preceding 6 months by their sleep partner; (2) presence of tooth attrition with exposed dentin; (3) reports of morning masticatory muscle fatigue or tenderness; and (4) presence of masseter muscle hypertrophy. Video-polysomnography was performed in the sleep laboratory for two nights. Sleep bruxism episodes were measured using masseter electromyography, visually inspected and then categorized into phasic or tonic episodes. Phasic episodes were categorized further into episodes with or without grinding sounds as evaluated by audio signals. Sleep bruxism subjects with reported grinding sounds had a significantly higher total number of phasic episodes with grinding sounds than subjects without reported grinding sounds or controls (Kruskal-Wallis/Steel-Dwass tests; P < 0.05). Similarly, sleep bruxism subjects with tooth attrition exhibited significantly longer phasic burst durations than those without or controls (Kruskal-Wallis/Steel-Dwass tests; P < 0.05). Furthermore, sleep bruxism subjects with morning masticatory muscle fatigue or tenderness exhibited significantly longer tonic burst durations than those without or controls (Kruskal-Wallis/Steel-Dwass tests; P < 0.05). These results suggest that each clinical sign and symptom of sleep bruxism represents different aspects of jaw motor activity during sleep.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between patterns of jaw motor activity during sleep and clinical signs and symptoms of sleep bruxism

Yoshida

Suganuma

Takaba

et al. 2016

Journal of Sleep Research

View full text Add to dashboard Cite

show abstract

“…Various clinical trials [55][56][57] reported that injections of BTX into the masseter muscles resulted in a sustained reduction of masseter hyperactivity. With BTX-A injections good, facial contour was achieved [58,59] and several cases were treated successfully [60]. Similarly, temporalis muscle hypertrophy can be treated with BTX injections [61].…”

Section: Masseter Muscle Hypertrophymentioning

confidence: 89%

The Emerging Role of Botulinum Toxin in the Treatment of Orofacial Disorders: Literature Update

Kumar

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Botulinum toxin (BTX) is a lethal neurotoxin produced by Gram-positive anaerobic bacterium called Clostridium botulinum. It is the first toxin used for therapeutic purposes since 1989. BTX treatment is relatively safe and efficacious, less invasive, conservative, and the effects are faster and reversible. The purpose of this article is to review the literature regarding the applications of BTX in the treatment of various orofacial disorders, their mechanism of action, contraindications, and complications. From the recently published literature, it is clear that the role of BTX as a therapeutic agent for several conditions is expanding. With the training of BTX-A injection techniques and adequate knowledge about treatment protocols, general dentists can safely administer BTX injections. The ability to use Botox as an adjuvant and primary mode of the treatment for various maxillofacial disorders offers exciting treatment options for dentists and patients in the future.

show abstract

“…BT-A injection is considered as a beneficial treatment modality in patients with masseter muscle hypertrophy. [36]…”

Section: Indications Of Botulinum Toxinmentioning

confidence: 99%

Botulinum toxin the poison that heals: A brief review

Dutta¹,

Passi

Singh

et al. 2016

Natl J Maxillofac Surg

View full text Add to dashboard Cite

Botulinum neurotoxins, causative agents of botulism in humans, are produced by Clostridium botulinum, an anaerobic spore-former Gram-positive bacillus. Botulinum neurotoxin poses a major bioweapon threat because of its extreme potency and lethality; its ease of production, transport, and misuse; and the need for prolonged intensive care among affected persons. This paper aims at discussing botulinum neurotoxin, its structure, mechanism of action, pharmacology, its serotypes and the reasons for wide use of type A, the various indications and contraindications of the use of botulinum neurotoxin and finally the precautions taken when botulinum neurotoxin is used as a treatment approach. We have searched relevant articles on this subject in various medical databases including Google Scholar, PubMed Central, ScienceDirect, Wiley Online Library, Scopus, and Copernicus. The search resulted in more than 2669 articles, out of which a total of 187 were reviewed. However, the review has been further constricted into only 54 articles as has been presented in this manuscript keeping in mind the page limitation and the limitation to the number of references. A single gram of crystalline toxin, evenly dispersed and inhaled, can kill more than one million people. The basis of the phenomenal potency of botulinum toxin (BT) is enzymatic; the toxin is a zinc proteinase that cleaves neuronal vesicle-associated proteins responsible for acetylcholine release into the neuromuscular junction. A fascinating aspect of BT research in recent years has been the development of the most potent toxin into a molecule of significant therapeutic utility. It is the first biological toxin which is licensed for the treatment of human diseases. The present review focuses on both warfare potential as well as medical uses of botulinum neurotoxin.

show abstract

Treatment of masseteric hypertrophy with botulinum toxin: A report of two cases

Cited by 40 publications

References 16 publications

Association between patterns of jaw motor activity during sleep and clinical signs and symptoms of sleep bruxism

Association between patterns of jaw motor activity during sleep and clinical signs and symptoms of sleep bruxism

The Emerging Role of Botulinum Toxin in the Treatment of Orofacial Disorders: Literature Update

Botulinum toxin the poison that heals: A brief review

Contact Info

Product

Resources

About